

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: N/A	
Policy Number: PHW.PDL.002	Effective Date: 01/01/2020 Revision Date: 10/2021	
Policy Name: Ophthalmic, Allergic Conjunctivitis		
Type of Submission – <u>Check all that apply</u> :		
 □ New Policy □ Revised Policy* ✓ Annual Review - No Revisions ✓ Statewide PDL - Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL. 		
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.		
Please provide any changes or clarifying information for the policy below:		
Q1 2022 annual review: no changes.		
Name of Authorized Individual (Please type or print):	Signature of Authorized Individual:	
Venkateswara R. Davuluri, MD	- Raulun	

CLINICAL POLICYOphthalmic, Allergic Conjunctivitis



Clinical Policy: Ophthalmic, Allergic Conjunctivitis

Reference Number: PHW.PDL.002

Effective Date: 01/01/2020 Last Review Date: 10/2021

Revision Log

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health and Wellness[®] that Allergic Conjunctivitis Ophthalmic Agents are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Ophthalmics, Allergic Conjunctivitis

A. Prescriptions That Require Prior Authorization

All prescriptions for a non-preferred Ophthalmic, Allergic Conjunctivitis must be prior authorized.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a non-preferred Ophthalmic, Allergic Conjunctivitis, the determination of whether the requested prescription is medically necessary will take into account the whether the beneficiary:

1. Has a history of therapeutic failure, contraindication, or intolerance to the preferred Ophthalmics Allergic Conjunctivitis.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a non-preferred Ophthalmic, Allergic Conjunctivitis. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. Approval Duration: 12 months

CLINICAL POLICY Ophthalmic, Allergic Conjunctivitis



Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q1 2022 annual review: no changes.	10/2021